Provocative (Drug) testing in inherited arrhythmias

Wataru Shimizu, Michael John Ackerman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Molecular genetic studies have established a link between a number of heritable channelopathies, including congenital long QT syndrome (LQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular tachycardia (CPVT), and mutations in genes encoding for ion channels or other membrane components, therefore, have become a golden standard for diagnosing these channelopathies. Clinical diagnosis by standard 12-lead electrocardiography (ECG) at baseline misses some patients, who are genetically affected by these channelopathies (so called concealed form). Therefore, there is a strong need to devise clinical tools to improve the sensitivity of clinical tests to establish the diagnosis of these heritable channelopathies. Provocative testing with catecholamines and pharmacologic testing with sodium channel blockers are critical diagnostic tests in the evaluation of these heritable channelopathies and enable to unmask LQTS, BrS, and CPVT in their concealed state.

Original languageEnglish (US)
Title of host publicationElectrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition
PublisherSpringer-Verlag London Ltd
Pages289-300
Number of pages12
ISBN (Print)9781447149781, 9781447149774
DOIs
StatePublished - Jan 1 2013

Fingerprint

Channelopathies
Cardiac Arrhythmias
Brugada Syndrome
Long QT Syndrome
Pharmaceutical Preparations
Sodium Channel Blockers
Ion Channels
Routine Diagnostic Tests
Catecholamines
Molecular Biology
Electrocardiography
Mutation
Membranes
Genes

Keywords

  • Arrhythmia
  • Brugada syndrome
  • Catecholamines
  • Diagnosis
  • Genes
  • Long-QT syndrome
  • QT interval
  • Sodium channel blocker
  • ST segment
  • Torsade de pointes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shimizu, W., & Ackerman, M. J. (2013). Provocative (Drug) testing in inherited arrhythmias. In Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition (pp. 289-300). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-4978-1_18

Provocative (Drug) testing in inherited arrhythmias. / Shimizu, Wataru; Ackerman, Michael John.

Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition. Springer-Verlag London Ltd, 2013. p. 289-300.

Research output: Chapter in Book/Report/Conference proceedingChapter

Shimizu, W & Ackerman, MJ 2013, Provocative (Drug) testing in inherited arrhythmias. in Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition. Springer-Verlag London Ltd, pp. 289-300. https://doi.org/10.1007/978-1-4471-4978-1_18
Shimizu W, Ackerman MJ. Provocative (Drug) testing in inherited arrhythmias. In Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition. Springer-Verlag London Ltd. 2013. p. 289-300 https://doi.org/10.1007/978-1-4471-4978-1_18
Shimizu, Wataru ; Ackerman, Michael John. / Provocative (Drug) testing in inherited arrhythmias. Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition. Springer-Verlag London Ltd, 2013. pp. 289-300
@inbook{f8b131c85a574b5487724492d5de61fb,
title = "Provocative (Drug) testing in inherited arrhythmias",
abstract = "Molecular genetic studies have established a link between a number of heritable channelopathies, including congenital long QT syndrome (LQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular tachycardia (CPVT), and mutations in genes encoding for ion channels or other membrane components, therefore, have become a golden standard for diagnosing these channelopathies. Clinical diagnosis by standard 12-lead electrocardiography (ECG) at baseline misses some patients, who are genetically affected by these channelopathies (so called concealed form). Therefore, there is a strong need to devise clinical tools to improve the sensitivity of clinical tests to establish the diagnosis of these heritable channelopathies. Provocative testing with catecholamines and pharmacologic testing with sodium channel blockers are critical diagnostic tests in the evaluation of these heritable channelopathies and enable to unmask LQTS, BrS, and CPVT in their concealed state.",
keywords = "Arrhythmia, Brugada syndrome, Catecholamines, Diagnosis, Genes, Long-QT syndrome, QT interval, Sodium channel blocker, ST segment, Torsade de pointes",
author = "Wataru Shimizu and Ackerman, {Michael John}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4471-4978-1_18",
language = "English (US)",
isbn = "9781447149781",
pages = "289--300",
booktitle = "Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - Provocative (Drug) testing in inherited arrhythmias

AU - Shimizu, Wataru

AU - Ackerman, Michael John

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Molecular genetic studies have established a link between a number of heritable channelopathies, including congenital long QT syndrome (LQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular tachycardia (CPVT), and mutations in genes encoding for ion channels or other membrane components, therefore, have become a golden standard for diagnosing these channelopathies. Clinical diagnosis by standard 12-lead electrocardiography (ECG) at baseline misses some patients, who are genetically affected by these channelopathies (so called concealed form). Therefore, there is a strong need to devise clinical tools to improve the sensitivity of clinical tests to establish the diagnosis of these heritable channelopathies. Provocative testing with catecholamines and pharmacologic testing with sodium channel blockers are critical diagnostic tests in the evaluation of these heritable channelopathies and enable to unmask LQTS, BrS, and CPVT in their concealed state.

AB - Molecular genetic studies have established a link between a number of heritable channelopathies, including congenital long QT syndrome (LQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular tachycardia (CPVT), and mutations in genes encoding for ion channels or other membrane components, therefore, have become a golden standard for diagnosing these channelopathies. Clinical diagnosis by standard 12-lead electrocardiography (ECG) at baseline misses some patients, who are genetically affected by these channelopathies (so called concealed form). Therefore, there is a strong need to devise clinical tools to improve the sensitivity of clinical tests to establish the diagnosis of these heritable channelopathies. Provocative testing with catecholamines and pharmacologic testing with sodium channel blockers are critical diagnostic tests in the evaluation of these heritable channelopathies and enable to unmask LQTS, BrS, and CPVT in their concealed state.

KW - Arrhythmia

KW - Brugada syndrome

KW - Catecholamines

KW - Diagnosis

KW - Genes

KW - Long-QT syndrome

KW - QT interval

KW - Sodium channel blocker

KW - ST segment

KW - Torsade de pointes

UR - http://www.scopus.com/inward/record.url?scp=84949436741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949436741&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-4978-1_18

DO - 10.1007/978-1-4471-4978-1_18

M3 - Chapter

AN - SCOPUS:84949436741

SN - 9781447149781

SN - 9781447149774

SP - 289

EP - 300

BT - Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition

PB - Springer-Verlag London Ltd

ER -